In a small cohort of KRASmut variants of pancreatic cancer patients, a new treatment regime of combining gemcitabine and a second generation of MEK inhibitor (cobimetinib) observed improved progression-free survival (PFS) among KRASG12R variants compared to the group of KRAS G12D and G12V [132]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.